English
新闻公告
More
化学进展 2010, Vol. 22 Issue (10): 1993-2002 前一篇   后一篇

• 综述与评论 •

肿瘤血管生成抑制剂*

董缙  姚硕蔚  徐云根**   

  1. (中国药科大学药物化学教研室,南京210009)
  • 收稿日期:2010-01-07 修回日期:2010-04-26 出版日期:2010-10-24 发布日期:2010-10-20
  • 通讯作者: 徐云根 E-mail:xu_yungen@hotmail.com
  • 基金资助:

    教育部留学回国人员科研启动基金;江苏省高校“青蓝工程”

Tumor Angiogenesis Inhibitors

Dong Jin   Yao Shuowei  Xu Yungen**   

  1. (Department of Medicinal Chemistry,China Pharmaceutical University, Nanjing 210009)
  • Received:2010-01-07 Revised:2010-04-26 Online:2010-10-24 Published:2010-10-20
  • Contact: Yungen Xu E-mail:xu_yungen@hotmail.com

肿瘤血管生成的药物治疗是当前有关肿瘤的热点研究领域,目前已经有数种肿瘤血管生成抑制剂上市。肿瘤血管生成抑制剂能够抑制肿瘤的生长和转移,甚至使肿瘤消退。此类药物的研究开发可为肿瘤患者提供高效、低毒,并且抗瘤谱更广的药物。本文综述了近年来血管生成抑制剂的研究进展。首先介绍了间接血管生成抑制剂,此类药物中的血管内皮细胞生长因子受体信号通路的药物是目前最成功的一类血管生成抑制剂。其次介绍了直接血管生成抑制剂,使用这类药物更有可能避免间接抑制剂所引起的血管生成援救反应。然后在其他途径肿瘤血管生成抑制剂部分,本文详细介绍了作用机制尚不明确的沙利度胺及其衍生物。最后,本文分析讨论了这类药物的开发所遇到的一些问题,如抗血管生成治疗的新理论的挑战和耐药性等,并指出了未来发展方向。

At present, drug inhibition of angiogenesis has become a hot topic in the treatment of tumor and several tumor angiogenesis inhibitors (TAIs) have been marketed. TAIs can suppress tumor growth and metastasis, and even induce tumor regression. Research and development on TAIs holds the promise of supplying drugs with high potency, low toxicity and broad-spectrum antitumor activity for tumor patients. This review summarized recent research progress in TAIs. First of all, indirect TAIs were introduced. Among indirect TAIs, VEGF inhibitor is the most successful TAI currently. Secondly, direct TAIs, which are unlikely switch on the angiogenic rescue program, were introduced. Thirdly, in the miscellaneous TAIs part, thalidomide and its derivatives, whose mechanisms of activity have not been defined well, were described in detail. Finally, several problems encountered in the research and development of TAIs, such as challenge from novel theory of anti-angiogenenic therapy and resistance, were analyzed and discussed, and future research directions were pointed out.

Contents 
1 Introduction
2 Indirect angiogenesis inhibitors
2.1 Inhibitors of VEGF/VEGFR signaling
2.2 Inhibitors of angiopoietin-Tie signaling 
3 Direct angiogenesis inhibitors
3.1 Metronomic chemotherapy
3.2 Inhibitors of endothelial-specific integrin/survival signaling
3.3 Miscellaneous direct angiogenesis inhibitors 
4 Miscellaneous angiogenesis inhibitors 
5 Questions needed to be considered
5.1 Mechanism of angiogenesis
5.2 Resistance of angiogenesis inhibitors
5.3 Clinical study design 
6 Future directions 
7 Conclusions
()

[1 ] 杨友华( Yang Y H ) . 中国处方药( Journal of China
Prescription Drug) ,2004,8(29) : 33—35
[2 ] Folkman J,Hochberg M J. Exp. Med. ,1973,138: 745—753
[3 ] Bergers G,Benjamin L E. Nat. Rev. Cancer. ,2003,3: 401—
410
[4 ] Ferrara N,Kerbel R S. Nature,2005,438: 967—974
[5 ] 何静( He J) ,冯奉仪( Feng F Y) . 临床药物治疗杂志
( Clinical Medication Journal) ,2005,3(2) : 16—20
[6 ] Gasparini G,Longo R,Toi M,Ferrara N. Nat. Clin. Pract.
Oncol. ,2005,2: 562—577
[7 ] Khosravi S P,Fernández P I. Cancer Invest. ,2008,26: 104—
108
[8 ] Otrock Z K,Mahfouz R A,Makarem J A,Shamseddine A I.
Blood Cells Mol. Dis. ,2007,39: 212—220
[9 ] Dvorak H F. J. Clin. Oncol. ,2002,20: 4368—4380
[10] Augustin H G,Koh G Y,Thurston G,Alitalo K. Nat. Rev.
Mol. Cell Biol. ,2009,10: 165—177
[11] Olsson A K,Dimberg A,Kreuger J,Claesson-Welsh L. Nat.
Rev. Mol. Cell Biol. ,2006,7: 359—371
[12] Veikkola T,Jussila L,Makinen T,Karpanen T,Jeltsch M,
Petrova T V,Kubo H,Thurston G,McDonald D M,Achen M
G,Stacker S A,Alitalo K. EMBO J. ,2001,20: 1223—1231
[13] Kiselyov A, Balakin K V, Tkachenko S E. Expert Opin.
Investig. Drugs,2007,16: 83—107
[14] 陈川( Chen C) ,俞德超(Yu D C) ,腾理送( Teng L S) ,中
国肿瘤生物治疗杂志( Chinese Journal of Cancer Biotherapy) ,
2007,14(3) : 291—300
[15] Ferrara N,Hillan K J,Gerber H P,Novotny W. Nat. Rev.
Drug Discov. ,2004,3: 391—400
[16] Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S,
Pattarini L,Chorianopoulos E,Liesenborghs L,Koch M,de M
M,Autiero M,Wyns S,Plaisance S,Moons L,van Rooijen N,
Giacca M,Stassen J M,Dewerchin M,Collen D,Carmeliet P.
Cell,2007,131: 463—475
[17] Holash J,Davis S,Papadopoulos N,Croll S D,Ho L,Russell
M,Boland P,Leidich R,Hylton D,Burova E,Ioffe E,Huang
T,Radziejewski C,Bailey K,Fandl J P,Daly T,Wiegand S J,
Yancopoulos G D,Rudge J S. Proc. Natl. Acad. Sci. USA,
2002,99: 11393—11398
[18] Posey J A,Ng T C,Yang B,Khazaeli M B,Carpenter M D,
Fox F,Needle M,Waksal H,LoBuglio A F. Clin. Cancer
Res. ,2003,9: 1323—1332
[19] Youssoufian H,Hicklin D J, Rowinsky E K. Clin. Cancer
Res. ,2007,13: 5544s—5548s
[20] Camidge D R,Eckhardt S G,Diab S,Gore L,Chow L,O′
Bryant C,Temmer E,Ervin-Haynes A,Katz T,Fox F,Cohen R
B. J. Clin. Oncol. ,2006,24: 3032—3038
[21] Wu Y,Zhong Z,Huber J,Bassi R,Finnerty B,Corcoran E,Li
H,Navarro E,Balderes P,Jimenez X,Koo H,Mangalampalli V
R,Ludwig D L,Tonra J R,Hicklin D J. Clin. Cancer Res. ,
2006,12: 6573—6584
[22] Strumberg D. Drugs Today ( Barc) ,2005,41: 773—784
[23] Wilhelm S,Carter C,Lynch M,Lowinger T,Dumas J,Smith R
A, Schwartz B, Simantov R, Kelley S. Nat. Rev. Drug
Discov. ,2006,5: 835—844
[24] Eisen T,Bukowski R M,Staehler M,Szczylik C,Oudard S,
Stadler W M,Schwartz B,Simantov R,Shan M,Escudier B.
2006 ASCO Annual Meeting Proceedings. Atlanta: J. Clin.
Oncol. ,2006,24: 4524
[25] Matsui J,Funahashi Y,Uenaka T,Watanabe T,Tsuruoka A,
Asada M. Clin. Cancer Res. ,2008,14: 5459—5465
[26] Atkins M,Jones C A,Kirkpatrick P. Nat. Rev. Drug Discov. ,
2006,5: 279—280
[27] Cabebe E,Wakelee H. Drugs Today ( Barc) ,2006,42: 387—
398
[28] Naumova E,Ubezio P, Garofalo A, Borsotti P, Cassis L,
Riccardi E,Scanziani E,Eccles S A,Bani M R,Giavazzi R.
Clin. Cancer Res. ,2006,2: 1839—1849
[29] Patyna S,Laird A D,Mendel D B,O′ farrell A M,Liang C,
Guan H,Vojkovsky T,Vasile S,Wang X,Chen J,Grazzini M,
Yang C Y, Haznedar J O, Sukbuntherng J, Zhong W Z,Cherrington J M,Hu-Lowe D. Mol. Cancer Ther. ,2006,5:
1774—1782
[30] Trudel S,Li Z H,Wei E,Wiesmann M,Chang H,Chen C,
Reece D,Heise C,Stewart A K. Blood,2005,105: 2941—
2948
[31] Hilberg F,Roth G J,Krssak M,Kautschitsch S,Sommergruber
W,Tontsch-Grunt U,Garin-Chesa P,Bader G,Zoephel A,
Quant J,Heckel A,Rettig W J. Cancer Res. ,2008,68:
4774—4782
[32] Teresa T,Tina T,John H,Ciardiello F. Curr. Cancer Ther.
Rev. ,2007,3: 236—241
[33] Wedge S R,Kendrew J,Hennequin L F,Valentine P J,Barry S
T,Brave S R,Smith N R,James N H,Dukes M,Curwen J O,
Chester R,Jackson J A,Boffey S J,Kilburn L L,Barnett S,
Richmond G H,Wadsworth P F,Walker M,Bigley A L,Taylor
S T,Cooper L,Beck S,Jürgensmeier J M,Ogilvie D J. Cancer
Res. ,2005,65: 4389—4400
[34] Garrett C R,Siu L L,El-Khoueiry A B,Buter J,Rocha-Lima C
M,Marshall J L,Kollia G,Velasquez L,Syed S,Feltquate D.
2008 ASCO Annual Meeting Proceedings. Chicago: J. Clin.
Oncol. ,2008,26: 4111
[35] Bhide R S,Lombardo L J,Hunt J T,Cai Z W,Barrish J C,
Galbraith S,Jeyaseelan R Sr,Mortillo S,Wautlet B S,Krishnan
B,Kukral D,Malone H,Lewin A C,Henley B J,Fargnoli J.
Mol. Cancer Ther. ,2010,9: 369—378
[36] Zhang Y,Guessous F,Kofman A, Schiff D,Abounader R.
IDrugs,2010,13: 112—121
[37] Deng M,Huang H,Dirsch O,Dahmen U. Eur. Surg Res. ,
2010,44: 82—95
[38] Morabito A,De M E, Di M M, Normanno N, Perrone F.
Oncologist,2006,11: 753—764
[39] Coxon A,Bush T,Saffran D,Kaufman S,Belmontes B,Rex K,
Hughes P,Caenepeel S,Rottman J B,Tasker A,Patel V,
Kendall R, Radinsky R, Polverino A. Clin. Cancer Res. ,
2009,15: 110—118
[40] Garton A J,Crew A P,Franklin M,Cooke A R,Wynne G M,
Castaldo L,Kahler J,Winski S L,Franks A,Brown E N,
Bittner M A,Keily J F,Briner P,Hidden C,Srebernak M C,
Pirrit C,O′Connor M,Chan A,Vulevic B,Henninger D,Hart
K,Sennello R,Li A H,Zhang T,Richardson F,Emerson D L,
Castelhano A L,Arnold L D,Gibson N W. Cancer Res. ,2006,
66: 1015—1024
[41] Williams R. Expert Opin. Investig. Drugs,2008,17: 1791—
1816
[42] Hutson T E,Bukowski R M. Clin. Genitourin. Cancer,2006,
4: 296—298
[43] Rugo H S,Herbst R S,Liu G,Park J W,Kies M S,Steinfeldt
H M,Pithavala Y K,Reich S D,Freddo J L,Wilding G. J.
Clin. Oncol. ,2005,23: 5474—5419
[44] Hanahan D. Science,1997,277: 48—50
[45] Yu Q. Future Medicine,2005,1: 475—484
[46] Kerbel R S. New Engl. J. Med. ,2008,358: 2039—2049
[47] Lobov I B,Brooks P C,Lang R A. Proc. Natl. Acad. Sci. ,
2002,99: 11205—11210
[48] Zhou B N,Johnson R K,Mattern M R,Fisher P W,Kingston D
G. Org. Lett. ,2001,3: 4047—4049
[49] Hodous B L,Geuns-Meyer S D,Hughes P E,Albrecht B K,
Bellon S,Bready J,Caenepeel S,Cee V J,Chaffee S C,Coxon
A,Emery M,Fretland J,Gallant P,Gu Y,Hoffman D,Johnson
R E,Kendall R,Kim J L,Long A M,Morrison M,Olivieri P
R,Patel V F,Polverino A,Rose P,Tempest P,Wang L,
Whittington D A,Zhao H. J. Med. Chem. ,2007,50: 611—
626
[50] Kerbel R S,Kamen B A. Nat. Rev. Cancer,2004,4: 423—
436
[51] Miller K D,Sweeney C J,Sledge G W. J. Clin. Oncol. ,2001,
19: 1195—1206
[52] Colleoni M,Rocca A,Sandri M T,Zorzino L,Masci G,Nolè F,
Peruzzotti G,Robertson C,Orlando L,Cinieri S,de B F,Viale
G,Goldhirsch A. An. Oncol. ,2002,13: 73—80
[53] Gluck S,Mackinnon J,Lau H,Syme R,Dort J,Gluck D. 2003
ASCO Annual Meeting Proceedings. Chicago: Proc. Am. Soc.
Clin. Oncol. ,2003,22: 2066
[54] Cohn D E,Valmadre S,Resnick K E,Eaton L A,Copeland L
J,Fowler J M. Gynecol. Oncol. ,2006,102: 134—139
[55] Emmenegger U,Man S,Shaked Y,Francia G,Wong J W,
Hicklin D J,Kerbel R S. Cancer Res. ,2004,64: 3994—4000
[56] Hanahan D,Bergers G,Bergsland E J. Clin. Invest. ,2000,
105: 1045—1047
[57] Browder T,Butterfield C E,Krling B M,Shi B,Marshall B,
O′Reilly M S,Folkman J. Cancer Res. ,2000,60: 1878—1886
[58] Huveneers S,Truong H,Danen H J. Int. J. Radiat. Biol. ,
2007,83: 743—751
[59] Schliemann C,Neri D. Biochem. Bioph. Acta. ,2007,1776:
175—192
[60] Loges S, Butzal M, Otten J, Schweizer M, Fischer U,
Bokemeyer C,Hossfeld D K,Schuch G,Fiedler W. Biochem.
Biophys. Res. Commun. ,2007,357: 1016—1020
[61] Perk J,Iavarone A,Benezra R. Nat. Rev. Cancer,2005,5:
603—614
[62] Henke E,Perk J,Vider J,de Candia P,Chin Y,Solit D B,
Ponomarev V,Cartegni L,Manova K,Rosen N,Benezra R.
Nat. Biotechnol. ,2008,26: 91—100
[63] Solomon S D,McMurray J J,Pfeffer M A,Wittes J,Fowler R,
Finn P,Anderson W F,Zauber A,Hawk E,Bertagnolli M. N.
Engl. J. Med. ,2005,352: 1071—1080
[64] Teo S K,Stirling D I,Zeldis J B. Drug Discov. Today,2005,
10: 107—114
[65] Aragon-Ching J B,Li H,Gardner E R,Figg W D. Recent
Patents Anticancer Drug Discov. ,2007,2: 167—174
[66] Ocio E M,Mateos M V,Maiso P,Pandiella A,San-Miguel J F.
Lancet Oncol. ,2008,9: 1157—1165
[67] Schey S A,Fields P,Bartlett J B,Clarke I A,Ashan G,Knight
R D,Streetly M,Dalgleish A G. J. Clin. Oncol. ,2004,22:3269—3276
[68] Kumar S,Raje N, Hideshima T, Ishitsuka K, Roccaro A,
Shiraishi N,Hamasaki M,Yasui H,Munshi N C,Richardson
P,Figg W D,Anderson K C. Leukemia,2005,19: 1253—
1261
[69] Jain R K. Science,2005,307: 58—62
[70] Page-McCaw A,Ewald A J,Werb Z. Nat. Rev. Mol. Cell
Biol. ,2007,8: 221—233
[71] Overall C M,Kleifeld O. Nat. Rev. Cancer,2006,6: 227—
239
[72] Konstantinopoulos P A, Karamouzis M V, Papatsoris A G,
Papavassiliou A G. Int. J. Biochem. Cell Biol. ,2008,40:
1156—1168
[73] Benedito R,Roca C,Srensen I,Adams S,Gossler A,Fruttiger
M,Adams R H. Cell,2009,137: 1124—1135
[74] Eberhard A,Kahlert S,Goede V,Hemmerlein B,Plate K H,
Augustin H G. Cancer Res. ,2000,60: 1388—1393
[75] Casanovas O,Hicklin D,Bergers G,Hanahan D. Cancer Cell,
2005,8: 299—309
[76] Willett C G,Boucher Y,Duda D G,di Tomaso E,Munn L L,
Tong R T,Kozin S V,Petit L,Jain R K,Chung D C,Sahani D
V,Kalva S P,Cohen K S,Scadden D T,Fischman A J,Clark J
W,Ryan D P,Zhu A X,Blaszkowsky L S,Shellito P C,Mino-
Kenudson M, Lauwers G Y. J. Clin. Oncol. , 2005, 23:
8136—8139
[77] Hida K,Klagsbrun M. Cancer Res. ,2005,65: 2507—2510
[78] Rudge J S,Holash J,Hylton D,Russell M,Jiang S,Leidich R,
Papadopoulos N,Pyles E A,Torri A,Wiegand S J,Thurston G,
Stahl N,Yancopoulos G D. Proc. Natl. Acad. Sci. ,2007,
104: 18363—18370
[79] Leighl N B,Paz-Ares L,Douillard J Y,Peschel C,Arnold A,
Depierre A,Santoro A,Betticher D C,Gatzemeier U,Jassem J,
Crawford J,Tu D,Bezjak A,Humphrey J S,Voi M,Galbraith
S,Hann K,Seymour L,Shepherd F A. J. Clin. Oncol. ,2005,
23: 2831—2839

[1] 顾顺心, 姜琴, 施鹏飞. 发光铱(Ⅲ)配合物抗肿瘤活性研究及应用[J]. 化学进展, 2022, 34(9): 1957-1971.
[2] 冯海弟, 赵璐, 白云峰, 冯锋. 纳米金属有机框架在肿瘤靶向治疗中的应用[J]. 化学进展, 2022, 34(8): 1863-1878.
[3] 陈晓峰, 王开元, 梁芳铭, 姜睿祺, 孙进. 外泌体递药系统及其在肿瘤治疗中的应用[J]. 化学进展, 2022, 34(4): 773-786.
[4] 王嘉莉, 朱凌, 王琛, 雷圣宾, 杨延莲. 循环肿瘤细胞及细胞外囊泡的纳米检测技术[J]. 化学进展, 2022, 34(1): 178-197.
[5] 荆晓东, 孙莹, 于冰, 申有青, 胡浩, 丛海林. 肿瘤微环境响应药物递送系统的设计[J]. 化学进展, 2021, 33(6): 926-941.
[6] 许惠凤, 董永强, 朱希, 余丽双. 新型二维材料MXene在生物医学的应用[J]. 化学进展, 2021, 33(5): 752-766.
[7] 刘加伟, 王婧, 王其, 范曲立, 黄维. 激活型有机光声造影剂的应用[J]. 化学进展, 2021, 33(2): 216-231.
[8] 王欣瑜, 赵富平, 张儒, 孙子茹, 刘胜男, 高清志. 抗肿瘤缺氧诱导因子-1的小分子抑制剂[J]. 化学进展, 2021, 33(12): 2259-2269.
[9] 官启潇, 郭和泽, 窦红静. 细胞膜修饰的纳米载体与肿瘤免疫治疗[J]. 化学进展, 2021, 33(10): 1823-1840.
[10] 郭珊, 周翔. 循环肿瘤细胞体内检测技术及其应用研究[J]. 化学进展, 2021, 33(1): 1-12.
[11] 吴晴, 唐一源, 余淼, 张悦莹, 李杏梅. 基于肿瘤微环境响应的DNA纳米结构递药系统[J]. 化学进展, 2020, 32(7): 927-934.
[12] 孙子茹, 刘胜男, 高清志. 靶向葡萄糖转运蛋白(GLUTs)抗癌药物的开发[J]. 化学进展, 2020, 32(12): 1869-1878.
[13] 宫苗, 王晓英, 王晓宁. 血液肿瘤相关生物标志物的电化学传感检测[J]. 化学进展, 2019, 31(6): 894-905.
[14] 徐子悦, 张运昌, 林佳乐, 王辉, 张丹维, 黎占亭. 药物输送体系构筑中的超分子组装策略[J]. 化学进展, 2019, 31(11): 1540-1549.
[15] 范昭璇, 赵亮, 张学记. 循环肿瘤DNA的检测:从数字化到测序[J]. 化学进展, 2019, 31(10): 1384-1395.
阅读次数
全文


摘要

肿瘤血管生成抑制剂*